文献速递消化系统肿瘤

CAPRI 2-GOIM试验:液体活检全面基因组分析捕获RAS/BRAFV600E野生型转移性结直肠癌患者的肿瘤异质性并识别癌症脆弱性

Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial.
PubMed 文献 · Ann Oncol · 2024-08-29

CAPRI 2-GOIM试验在RAS/BRAFV600E野生型转移性结直肠癌患者一线治疗前,分别用FoundationOne CDx检测肿瘤组织DNA和FoundationOne Liquid CDx检测血浆循环肿瘤DNA进行全面基因组分析。205例可评估患者中,两种检测一致性为61.4%,游离DNA肿瘤分数≥10%时升至72.7%;液体活检可检出更多基因组变异,53.2%患者至少有一个可操作变异。

要点

  • 液体活检全面基因组分析与组织检测一致性61.4%,肿瘤分数≥10%时升至72.7%。
  • 液体活检检出更多基因组变异,包括6例KRAS和NRAS变异。
  • 53.2%患者至少有一个ESCAT I至IIIB级可操作变异。

核心结论

  • 基线液体活检全面基因组分析可行,与肿瘤组织全面基因组分析高度一致,能更好反映肿瘤异质性,并在约半数RAS/BRAFV600E野生型转移性结直肠癌患者中识别出额外的可操作基因组变异,具有临床信息价值。

研究设计与样本

  • CAPRI 2-GOIM试验评估由循环肿瘤DNA驱动的以西妥昔单抗为基础的三线序贯治疗的疗效与安全性,入组经本地实验室确定为RAS/BRAFV600E野生型的转移性结直肠癌患者。
  • 一线治疗前分别用FoundationOne CDx(324基因)检测肿瘤组织DNA、FoundationOne Liquid CDx(324基因)检测血浆循环肿瘤DNA进行全面基因组分析。

主要发现

  • 207例患者中2例(0.96%)经FoundationOne Liquid CDx未检出循环肿瘤DNA,无患者肿瘤分数低于1%,205例中140例(68.3%)检出肿瘤分数≥10%的高循环肿瘤DNA。
  • 205例中164例(80%)两种检测结果均可获得,两检测一致性为61.4%,FoundationOne Liquid CDx肿瘤分数≥10%时一致性升至72.7%。
  • 涉及抗表皮生长因子受体耐药相关基因的一致性在164例中137例(83%)一致,FoundationOne Liquid CDx肿瘤分数≥10%时升至91.5%。
  • FoundationOne Liquid CDx较FoundationOne CDx检出更多基因组改变,包括6例KRAS和NRAS变异;205例中109例(53.2%)至少有一个按ESCAT分级为I至IIIB级的可操作基因组变异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Emerging evidence supports tumor tissue-based comprehensive genomic profiling (CGP) in metastatic colorectal cancer (mCRC). Data on liquid biopsy-based circulating tumor DNA (ctDNA) CGP are scarce and mainly retrospective. Prospective comparison between the two tests is not currently available. MATERIALS AND METHODS: The CAPRI 2-GOIM trial investigates efficacy and safety of ctDNA-driven, cetuximab-based sequence of three treatment lines in patients with RAS/BRAFV600E wild-type (WT) mCRC, as determined by the local laboratory. Before first-line therapy, CGP is carried out with FoundationOne (F1) CDx and F1 Liquid (F1L) CDx (324 genes) on tumor tissue DNA and plasma ctDNA, respectively. RESULTS: For 2/207 (0.96%) patients, no ctDNA was detected by F1L CDx. No patient displayed tumor fraction (TF) below 1%, whereas elevated ctDNA (TF ≥ 10%) was detected among 140/205 (68.3%) patients. One thousand and thirteen genomic variants were identified. F1L CDx found KRAS, NRAS, or BRAFV600E alterations in 19 patients, whose tumors were classified as RAS/BRAFV600E WT by the local laboratory. Both F1 CDx and F1L CDx were available for 164/205 (80%) patients. A concordance of 61.4% between the two tests was observed. The concordance increased to 72.7% for F1L CDx with TF ≥ 10%. Concordance for genes potentially involved in anti-epidermal growth factor receptor resistance was found in 137/164 (83%) patients, increasing to 91.5% for F1L CDx with TF ≥ 10%. A higher number of genomic alterations was detected by F1L CDx compared with F1 CDx, including six cases with KRAS and NRAS alterations. Overall, 109/205 (53.2%) patients displayed at least one actionable genomic alteration (I to IIIB), according to the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT). CONCLUSION: Baseline liquid biopsy-based CGP is feasible, has high concordance with tumor tissue-based CGP, could better recapitulate tumor heterogeneity, and is clinically informative by identifying additional actionable genomic alterations in approximately half of RAS/BRAFV600E WT mCRC patients.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ciardiello D, Boscolo Bielo L, Napolitano S, et al. Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial. Ann Oncol. 2024. PMID: 39214459. doi:10.1016/j.annonc.2024.08.2334

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。